UNSPSC 51141557: Eterobarb

This classification denotes a barbiturate with the molecular formula C16H20N2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 432SI047GA, chemically known as 2,4,6(1h,3h,5h)-pyrimidinetrione, 5-ethyl-1,3-bis(methoxymethyl)-5-phenyl- but generally known as eterobarb, which bears US NIH Compound Identifier 33925. European Medicines Agency schedules Eterobarb in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07269MIG. The term ETEROBARB is an International Non-Proprietary Name.

UNSPSC 51141557 Eterobarb is a Commodity code that covers pharmaceutical supply and drug-related products procured by state and local health agencies. The recent solicitations indexed under this code reflect state and local procurement of naloxone (opioid antagonist), safe drug deactivation systems, and generic multi-source pharmaceuticals and over-the-counter products distributed through authorized pharmacy wholesalers and cooperative purchasing vehicles. State and local issuing bodies acquiring under this code include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances. Procurement mechanisms vary from straightforward IFBs for direct county purchases to RFPs for statewide pharmaceutical contract frameworks and RFIs for exploratory market intelligence on direct-to-manufacturer prescription programs.

Recent activity spans Florida, Texas, and Minnesota, with the most active documented solicitations coming from cooperative purchasing arrangements and state health agencies. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, with a response deadline of July 26, 2023. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted an RFP for generic multi-source pharmaceuticals and OTC products on January 20, 2026 with a March 26, 2026 deadline, requiring vendor participation through three authorized wholesalers (AmerisourceBergen Drug Corporation / Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC) and a two-year initial contract term. The Texas Health and Human Services Commission issued an RFI in April 2026 on a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program to gather vendor capabilities and market intelligence regarding direct contracting between state pharmacy benefit programs and manufacturers outside traditional PBM and wholesaler arrangements.